ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

3 Best Growth Stocks to Own for the Next 10 Years

Various icons of the companies belonging to the Facebook metaverse on the black screen of the smartphone.

During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means looking back at the past performance of the stocks they own or those on their watchlist(s).  

While it’s true that you want to look for stock price growth, you also want to invest in companies that have a history of increasing revenue and earnings. This growth helps to ensure that a company can sustain a higher stock price over time.

This simple action can remind you that, over time, buying and holding quality stocks tends to pay off. It’s also a good reminder that these consistent outperformers are often large-cap stocks that have a proven track record of delivering for investors no matter what the economy is doing.  

Here are three growth stocks that have given investors strong performance for the last 10 years and are likely to be among the market leaders in the next 10 years.  

This Dividend King Continues to Deliver for Investors 

AbbVie Inc. (NYSE: ABBV) is a good example of how dividend stocks and growth can co-exist. The biopharmaceutical company is one of the best medical stocks, delivering a total return of 435.38% in the last 10 years. That’s a significant outperformance compared to the 14.6% historical average yearly return of the S&P 500. However, it’s particularly notable that ABBV stock has been up 34.6% in the last 12 months, even though 2023 revenue came in about 6% lower on a year-over-year (YoY) basis. 

That dip was due, in part, to pressure from biosimilar competition for its flagship drug Humira. However, in the first two quarters of 2024, the company is posting YoY beats in revenue as new drugs such as Skyrizi and Rinvoq are picking up some of the slack. And by 2027, those two drugs are expected to deliver $27 billion in revenue.  

ABBV stock also has an attractive dividend that has been increasing for 52 consecutive years and currently has a 3.14% yield.  

Meta Continues to Have the Right Formula for Growth 

With all the talk of the company’s commitment to the metaverse, Meta Platforms Inc. (NASDAQ: META) is showing investors that it hasn’t forgotten how its bread is buttered. The parent company of Facebook and Instagram continues to dominate the social media and online advertising space. In fact, digital advertising continues to drive revenue growth. 

This revenue growth is providing Meta with the cash that it needs to fund its investments in artificial intelligence (AI), including the metaverse. This may be a drag on earnings in the short term, but this is about stocks to own for the long term. META stock has delivered a total return of 587% in the last 10 years, and there’s no reason to believe it can’t continue to outperform. 

As further proof, Meta has shown an ability to get its balance sheet in order and even issued a dividend for the first time in its history. While this isn’t a reason to own a growth stock like META, it does give investors another reason to hold onto the stock during times of volatility.  

This Innovative Company Remains on the Leading Edge 

Intutitive Surgical Inc. (NASDAQ: ISRG) has delivered a total return of over 800% over the last 10 years. That's almost 5x the performance of the S&P 500 in that time. However, that shouldn’t deter investors from getting involved with this next-generation medical device company. In fact, the growth is likely to accelerate in the next 10 years.  

The company’s da Vinci robotic surgical systems are the standard in minimally invasive care. The company has a huge addressable market, as evidenced by the more than 2.2 million procedures performed by the da Vinci system in 2023.  

While it’s easy to focus on the millions of dollars the company receives from selling one of these systems, this is a recurring revenue story. In its most recent earnings report, the company reported that 83% of its revenue came from recurring revenue.  

Revenue was up 14% year over year in 2023, and the company is on pace for even stronger growth through the first two quarters of 2024.  

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.